Clinical Trial Update: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) [Phase 3]

View source ↗

Summary

Phase 3 study of crenezumab versus placebo in prodromal to mild Alzheimer's disease was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Crenezumab

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2020-07-16